focus -WSS

focus

author：entertainment 2025-09-29 01:08:31 - browse：98354

Alex Hogan/STAT

The J.P. Morgan Healthcare Conference is upon us, bringing its frenetic meetings, crowded hallways, and hotel rooms so expensive that even the pharmaceutical industry complains about what a free market does to the prices of scarce goods.

This year’s iteration, starting Monday in San Francisco, finds the biotech industry, in particular, in a curious spot. After a volatile 2023 that saw biotech stocks hit five-year lows in the fall, the sector had a bull run in the final weeks of the year, spurred by some high-dollar merger agreements and a prevailing sense that the macroeconomic winds were finally shifting in biotech’s direction.

Meanwhile, companies selling digital health services like telemedicine, health plans for virtual care, and AI tools for payers face a crucial year as they scramble to make good on profitability projections. Those companies, along with the country’s most powerful health systems, are seriously exploring AI, even ChatGPT, to help them meet financial milestones.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Pharma companies must ensure equitable access to obesity drugs

entertainment

leisure time

WSS

Novo Nordisk to expand supply of Wegovy for U.S. patients

Novo Nordisk to expand supply of Wegovy for U.S. patients

Health care court cases: Humana, Sutter, Novant

Woodcock on FDA’s accelerated approval and her next chapter

Cheap, fast test for Zika and dengue could cost just $1

New report analyzes digital physical therapy solutions' effectiveness

focus

focus

knowledge

Heart attack and stroke risk calculators need revising

ARCH Venture Partners is raising $3 billion for a life sciences fund

State Dept. review finds Biden bears some blame for Afghanistan failures

Do digital therapeutics have a future in medicine?

Novavax promises a turnaround & Lilly roils the obesity market

Curing rare childhood diseases will falter unless Congress steps up

BioMarin wins approval for gene therapy to treat hemophilia A

New Ultima Genomics DNA sequencer can read genome for $100

Walensky prepares to leave CDC — and Congress — behind

Commercial surrogacy can be ethical, despite pope’s claims

knowledge

Vertigo drug brings hope for rare neuron disorder, Niemann

Medical device trials still don't enroll enough women, study finds

Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

New Ultima Genomics DNA sequencer can read genome for $100

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Curing rare childhood diseases will falter unless Congress steps up

leisure time

entertainment

leisure time

hotspot